Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
Analytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
Professional Services
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
Trust and Security
PatentBench
LLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How AstraZeneca is reformulating durvalumab (Imfinzi) for subcutaneous delivery using Halozyme ENHANZE technology — and what it means for the SC checkpoint inhibitor race.
Article | Report A 2026 landscape of advanced nuclear reactor fuel technology: ATF compositions, HALEU supply chains, REMIX recycling, TRISO fuels, and closed fuel cycle strategies.
Article | Report AbbVie's Rinvoq (upadacitinib) faces a pivotal 2026: expanding into atopic dermatitis and AS while navigating JAK inhibitor class-wide safety labeling scrutiny.
Article | Report Merck's Keytruda faces a 2028 patent cliff. Explore pembrolizumab successor pipeline, fixed-dose combinations, and ADC partnerships shaping the post-cliff strategy.
Article | Report A 2026 patent and literature landscape of wearable continuous health monitoring: key technology clusters, top assignees, emerging directions, and strategic implications.
Article | Report Capivasertib (AZD5363) targets the PI3K/AKT/PTEN pathway in HR+/HER2- breast cancer. Explore the CAPItello-291 Phase III rationale, IP signals, and combination strategy.
Article | Report An overview of tarlatamab's DLL3-targeting BiTE mechanism, the DeLLphi-312 first-line SCLC trial design, and IO + bispecific combination rationale for extensive-stage SCLC.
Article | Report Patritumab deruxtecan (HER3-DXd) is reshaping post-EGFR TKI NSCLC treatment. Explore the patent race, clinical data, and Daiichi Sankyo/AstraZeneca strategy.
Article | Report Explore the 2026 wearable continuous health monitor technology landscape: key patent trends, R&D signals, and innovation intelligence from PatSnap Eureka.
Article | Report LAG-3 combination therapy relatlimab plus nivolumab vs. pembrolizumab in adjuvant melanoma: checkpoint mechanisms, clinical context, and IP landscape analysis.
Article | Report TERN-501 is a selective THRβ agonist developed by Terns Pharmaceuticals for MASH. Explore its patent landscape, mechanism, and competitive positioning against resmetirom.
Article | Report Icotrokinra (JNJ-2113) is the first oral IL-23 receptor peptide inhibitor in Phase III for psoriasis. Explore J&J's patent strategy and the race to challenge injectable biologics.
Article | Report Iptacopan vs. ravulizumab in PNH: how oral Factor B inhibition reshapes complement therapy, hemoglobin endpoints, and the competitive landscape.
Article | Report How GSK depemokimab and tezepelumab are reshaping severe asthma treatment beyond eosinophil-high phenotypes — a deep dive into the alarmin axis competitive race.
Article | Report How amivantamab redefined EGFR exon 20 insertion NSCLC treatment — and why the HER2 pipeline is racing to replicate that blueprint. Patent and clinical data analysis.